About the Authors

Marcella Sarzotti-Kelsoe, Leila Needham, Daniel Ozaki
Duke University, Center for AIDS Research Central QA Unit, Durham, North Carolina, United States of America

Josephine Cox
International AIDS Vaccine Initiative, Rockville, Maryland, United States of America

Naana Cleland
Henry M. Jackson Foundation for the Advancement of Military Medicine–Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America

Thomas Denny, Leila Needham
Duke Human Vaccine Institute, Center for HIV/AIDS Vaccine Immunology, Durham, North Carolina, United States of America

John Hural
HIV Vaccine Trials Network, Seattle, Washington, United States of America

Isaac R. Rodriguez-Chavez
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America

Gwynneth Stevens
International AIDS Vaccine Initiative, Johannesburg, Gauteng, South Africa

Timothy Stiles
Qualogy Ltd, Kettering, United Kingdom

Tony Tarragona-Fiol
International AIDS Vaccine Initiative Core Laboratory, Imperial College London, London, United Kingdom

Anita Simkins
AlphaVax Human Vaccines, Research Triangle Park, North Carolina, United States of America

Corresponding Author

msarzott@duke.edu

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

ICMJE criteria for authorship read and met: MSK JC NC TD JH LN DO IRRC GS TS TTF AS. Wrote the first draft of the paper: MSK IRRC AS. Contributed to the writing of the paper: MSK JC NC TD JH LN DO IRRC GS TS TTF AS.